Rigid Macrocycle Metal Complexes as CXCR4 Chemokine Receptor Antagonists: Influence of Ring Size

• Published in: Pharmaceutics Vol. 16; no. 8; p. 1000
• Main Authors: Renard, Isaline, D'huys, Thomas, Burke, Benjamin P, Ajoleza, Trisha, Cain, Amy N, Funwie, Neil L, Khan, Abid, Maples, Danny L, Maples, Randall D, Matz, Dallas L, McRobbie, Graeme, Ullom, Robert, Prior, Timothy J, Linder, Douglas P, Van Loy, Tom, Hubin, Timothy J, Schols, Dominique, Archibald, Stephen J
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.07.2024; MDPI
• Subjects: Acquired immune deficiency syndrome; AIDS; AMD3100; cancer therapeutics; Cancer therapies; Chemokines; CXCR4; cyclam; Hydrocarbons; Ligands; macrocycle; Metastasis; Nitrogen; Plerixafor; Plerixafor; AMD3100; cancer therapeutics; CXCR4; macrocycle; cyclam; molecular imaging
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics16081000

Understanding the role of chemokine receptors in health and disease has been of increasing interest in recent years. Chemokine receptor CXCR4 has been extensively studied because of its defined role in immune cell trafficking, HIV infection, inflammatory diseases, and cancer progression. We have developed high affinity rigidified CXCR4 antagonists that incorporate metal ions to optimize the binding interactions with the aspartate side chains at the extracellular surface of the CXCR4 chemokine receptor and increase the residence time. Cross- and side-bridged tetraazamacrocylic complexes offer significant advantages over the non-bridged molecular structures in terms of receptor affinity, potential for radiolabelling, and use in therapeutic applications. Our investigation has been extended to the influence of the ring size on bridged tetraazamacrocyclic compounds with the addition of two novel chelators (bis-cross-bridged homocyclen and bis-cross-bridged cyclen) to compare to the bis-bridged cyclam, along with novel metal complexes formed with copper(II) or zinc(II). The in vitro biological assays showed that all of the zinc(II) complexes are high affinity antagonists with a marked increase in CXCR4 selectivity for the bis-cross-bridged cyclen complex, whereas the properties of the copper(II) complexes are highly dependent on metal ion geometry. X-ray crystal structural data and DFT computational studies allow for the rationalisation of the relative affinities and the aspartate residue interactions on the protein surface. Changing the ring size from 14-membered can increase the selectivity for the CXCR4 receptor whilst retaining potent inhibitory activity, improving the key pharmacological characteristics.